TScan Therapeutics, Inc.
TCRX
$0.33
-$0.01-4.26%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 17.84% | 16.00% | 35.83% | -19.48% | -16.71% |
| Total Depreciation and Amortization | 0.14% | 2.21% | 1.69% | -25.32% | -37.46% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -0.77% | 15.04% | -14.59% | 132.43% | 21.71% |
| Change in Net Operating Assets | -218.13% | 117.37% | -324.78% | -28.67% | -82.32% |
| Cash from Operations | 17.23% | 35.40% | -16.74% | -16.28% | -26.85% |
| Capital Expenditure | 61.45% | 95.43% | 80.74% | -4.01% | -48.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -46.77% | 141.99% | 251.32% |
| Cash from Investing | -100.96% | -100.52% | -45.67% | 139.56% | 243.66% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -48.17% | -- | -80.69% | -100.00% | -99.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | -- | -100.06% |
| Cash from Financing | -14.66% | -- | -99.84% | -100.00% | -99.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -282.53% | 0.94% | -137.52% | 100.10% | -84.96% |